Faculty: Romina Mizrahi, MD, PhD

Romina Mizrahi, MD, PhDRomina Mizrahi, MD, PhD
Associate Professor, Department of Psychiatry
Clinician Scientist, Schizophrenia program, PET Centre, CAMH

General Research Areas: Clinical Pharmacology; Neuropharmacology; Psychopharmacology
Imaging Brain Chemistry in Psychosis and Patients at Clinical High Risk for Psychosis

My goal is to develop a better understanding of how the brain functions in-vivo. Specifically, my focus is the pathophysiology of the early course of schizophrenia and its treatment. In pursuit of this goal I use phenomenology and positron emission tomography (PET).

Selected Publications:

Suridjan I, Rusjan PM, Voineskos AN, Strafella AP, Wilson AA, Houle S, Mizrahi R. Neuroinflammation in healthy aging: a PET study using a novel translocator protein 18kda (TSPO) radioligand, [18F]-FEPPA. Neuroimage 2014 Jan;84(1): 868-75.

Mizrahi R, Kenk M, Suridjan I, Boileau I, George TP, McKenzie K, Wilson AA, Houle S, Rusjan PM (2014) Stress-induced dopamine response in subjects at clinical high risk for schizophrenia with and without concurrent cannabis use. Neuropsychopharmacology 39(6):1479-89.

Mizrahi R, Rusjan PM, Vitcu I, Ng A, Wilson AA, Houle S and Bloomfield PM, Whole body biodistribution and radiation dosimetry in humans of a new PET ligand, [18F]-FEPPA, to image translocator protein (18 kDa). Molecular Imaging and Biology, 2013 Jun;15(3):353-9.

Rusjan PM, Wilson AA, Mizrahi R, Boileau I, Chavez SE, Lobaugh NJ, Kish SJ, Houle S and Tong J, Mapping human brain fatty acid amide hydrolase activity with PET. Journal of Cerebral Blood Flow and Metabolism, 2013 Mar;33(3):407-14.

Suridjan I, Rusjan P, Addington J, Wilson AA, Houle S and Mizrahi R, Dopamine D2 and D3 binding in people at clinical high risk for schizophrenia, antipsychotic-naïve patients and healthy controls while performing a cognitive task. Journal of Psychiatry and Neuroscience, 2013 Mar;38(2):98-106.

Mizrahi R, Suridjan I, Kenk M, George TP, Wilson A, Houle S and Rusjan P, Dopamine response to psychosocial stress in chronic cannabis users: a PET study with [11C]-(+)-PHNO. Neuropsychopharmacology, 2013 Mar;38(4):673-82.

Mizrahi R, Rusjan P, Vitcu I, Ng A, Wilson AA, Houle S and Bloomfield PM, Whole-body distribution and radiation dosimetry of [11C]-(+)-PHNO, a D2/3 agonist ligand. Journal of Nuclear Medicine, 2012 Nov;53(11):1802-6.

Mizrahi R, Rusjan P, Kennedy JL, Pollock B, Muslant B, Suridjdan I, Deluca V, Wilson AA, and Houle S, Translocator Protein (18 kDa) polymorphism (rs 6971) explains in-vivo brain binding affinity of the PET radioligand [18F]-FEPPA. Journal of Cerebral Blood Flow & Metabolism. 2012 Jun;32(6):968-72.

Mizrahi R, Addington J, Rusjan PM, Suridjan I, Ng A, Boileau I, Pruessner JC, Remington G, Houle S, Wilson AA. Increased stress-induced dopamine release in psychosis. Biological Psychiatry. 2012; 71(6):561-7.

Mizrahi, R; Agid O; Borlido C, Suridjan I; Rusjan P, Houle S, Remington G, Wilson, AA; Kapur S. Effects of antipsychotics on D3 receptors: a clinical PET study in first episode antipsychotic naïve patients with Schizophrenia using [11C]-(+)-PHNO. Schizophrenia Research. 2011;131(1-3):63-8.

Rusjan P, Wilson A, Bloomfield P, Vitcu I, Meyer J, Houle S, Mizrahi, R. Quantitation of translocator protein binding in human brain with the novel radioligand F-18-FEPPA and positron emission tomography. Journal of Cerebral Blood Flow & Metabolism. 2011; 31(8):1807-16.

Mizrahi R. Advances in PET analyses of stress and dopamine. Hot Topics Special Edition. Invited review for Neuropsychopharmacology, 2010 Jan;35(1):348-9.

Mizrahi R, Houle S, Vitcu I, Ng A, Wilson AA. Side effects profile in human of [11C]-(+)-PHNO, a dopamine D2/3agonist ligand for positron emission tomography. Journal of Nuclear Medicine, 2010 Mar;51(3):496-7. PA.

Mizrahi R, Addington J, Remington G, Kapur S. Attributional style as a factor in Psychosis and antipsychotic treatment. Schizophrenia Research – 2008 Sep; 104(1-3):220-7.

Mamo D, Graff A, Mizrahi R, Romeyer F, Shammi CM, Kapur S. Differential effects of Aripiprazole on D2, 5HT2, and 5HT1A Receptor in Patients with Schizophrenia – a triple tracer PET study –American Journal of Psychiatry- 2007 Sep;164(9):1411-7.

Mizrahi R, Rusjan P, Agid O, Graff, Mamo D, Zipursky RB, Kapur S. Subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors - PET study in first episode schizophrenia. American Journal of Psychiatry 2007 Apr;164(4):630-7.

Contact:

Centre for Addiction and Mental Health – CAMH 
250 College Street
Toronto, ON, M5T 1R8 
Telephone: (416) 535-8501 Ext. 34508 
Fax (416) 260-4164 
Email: romina.mizrahi@camhpet.ca or romina_mizrahi@camh.ca 

Back to Top